Zobrazeno 31 - 40
of 162
pro vyhledávání: ''
Autor:
Thahir Farzan, Kimberly R. Kalli, Paul Haluska, Marc A. Becker, S. John Weroha, Tai W. Wong, Sean C. Harrington, James Krempski, Xiaonan Hou
Publikováno v:
Molecular Cancer Therapeutics. 12:2909-2916
Ovarian cancer mortality ranks highest among all gynecologic cancers with growth factor pathways playing an integral role in tumorigenesis, metastatic dissemination, and therapeutic resistance. The HER and VEGF receptor (VEGFR) are both overexpressed
Autor:
Federica Di Nicolantonio, Alberto Bardelli, Enzo Medico, Davide Zecchin, Sabrina Arena, Margherita Gallicchio, Miriam Martini, Alice Bartolini, Valentina Boscaro, Carlotta Cancelliere, Emily Crowley, Ludovic Barault
Publikováno v:
Molecular Cancer Therapeutics; Vol 12
A critical step toward defining tailored therapy in patients with cancer is the identification of genetic interactions that may impair—or boost—the efficacy of selected therapeutic approaches. Cell models able to recapitulate combinations of gene
Autor:
Alice C. Fan, Hua Fan-Minogue, Sanjiv S. Gambhir, Ramasamy Paulmurugan, Dean W. Felsher, Sandhya Bodapati, Tarik F. Massoud, David E. Solow-Cordero
Publikováno v:
Molecular Cancer Therapeutics. 12:1896-1905
Deregulation of c-Myc plays a central role in the tumorigenesis of many human cancers. Yet, the development of drugs regulating c-Myc activity has been challenging. To facilitate the identification of c-Myc inhibitors, we developed a molecular imagin
Publikováno v:
Molecular Cancer Therapeutics. 12:1579-1590
The EGF receptor (EGFR) is a proto-oncogene commonly dysregulated in several cancers including non–small cell lung carcinoma (NSCLC) and, thus, is targeted for treatment using tyrosine kinase inhibitors (TKI) such as erlotinib. However, despite the
Autor:
Liqun Huang, Nengtai Ouyang, Basil Rigas, Gang Xie, Ka-Wing Cheng, Timothy S. Wiedmann, Ninche Alston, Gerardo G. Mackenzie, Chi Chun Wong
Publikováno v:
Molecular Cancer Therapeutics. 12:1417-1428
Phospho-sulindac is a sulindac derivative with promising anticancer activity in lung cancer, but its limited metabolic stability presents a major challenge for systemic therapy. We reasoned that inhalation delivery of phospho-sulindac might overcome
Autor:
Hyun-Jin Nam, Seock-Ah Im, Young-Kwang Yoon, Tae-You Kim, Sae-Won Han, Hwang-Phill Kim, Paul Elvin, Yung-Jue Bang, Ahrum Min, Do-Youn Oh, Sang-Hyun Song
Publikováno v:
Molecular Cancer Therapeutics. 12:16-26
Src is a nonreceptor tyrosine kinase involved in the cross-talk and mediation of many signaling pathways that promote cell proliferation, adhesion, invasion, migration, and tumorigenesis. Increased Src activity has been reported in many types of huma
Autor:
Roger S. Lo, Varsha Tembe, Helen Rizos, Richard F. Kefford, John F. Thompson, James S. Wilmott, Richard A. Scolyer, Julie Howle, Raghwa Sharma, Georgina V. Long
Publikováno v:
Molecular Cancer Therapeutics. 11:2704-2708
Targeted therapies are increasingly being used to treat a variety of cancers. Their efficacy depends upon the accurate detection and targeting of a specific mutation or aberration in the tumor. All cancers, such as melanoma, are molecularly heterogen
Autor:
Nan Liu, Yin Sun, Chaozhao Liang, Ryan K. Thor, Elaine Hsia, Robert Damoiseaux, Boxiao Ding, Sheng Tai, Sunita Bhuta, Jiaoti Huang
Publikováno v:
Molecular Cancer Therapeutics. 11:1320-1331
PI3K/AKT/mTOR pathway plays a key role in the tumorigenesis of many human cancers including prostate cancer. However, inhibitors of this pathway, such as Rad001, have not shown therapeutic efficacy as a single agent. Through a high-throughput screen
Autor:
Marc Ladanyi, Mark G. Kris, Maria E. Arcila, Gregory J. Riely, Maureen F. Zakowski, Valerie W. Rusch, M. Catherine Pietanza, Camelia S. Sima, Christopher Lau, Paul K. Paik, Jamie E. Chaft
Publikováno v:
Molecular Cancer Therapeutics. 11:485-491
Phosphoinositide-3-kinase catalytic alpha polypeptide (PIK3CA) encodes the p110α subunit of the mitogenic signaling protein phosphoinositide 3-kinase (PI3K). PIK3CA mutations in the helical binding domain and the catalytic subunit of the protein hav
Autor:
Fawn Qian, Justin Lesch, Yu-Chien Chou, Frauke Bentzien, Jenny Tan, A. Douglas Laird, Stefan Engst, Felix Chu, Kyoko Yamaguchi, F. Michael Yakes, Andrew You, Belinda Cancilla, Yongchang Shi, Jason Chen, Peiwen Yu, Lillian Lee, Jessica Orf, Alison Joly
Publikováno v:
Molecular Cancer Therapeutics. 10:2298-2308
The signaling pathway of the receptor tyrosine kinase MET and its ligand hepatocyte growth factor (HGF) is important for cell growth, survival, and motility and is functionally linked to the signaling pathway of VEGF, which is widely recognized as a